Nottingham Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Nottingham Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-15,935	Closed	-$54K	–	115
2017 Q3	$54K	Hold	15,935	–	–	0.01%	108
2017 Q2	$39K	Hold	15,935	–	–	0.01%	112
2017 Q1	$36K	Hold	15,935	–	–	0.01%	111
2016 Q4	$34K	Hold	15,935	–	–	0.01%	112
2016 Q3	$53K	Hold	15,935	–	–	0.01%	109
2016 Q2	$50K	Hold	15,935	–	–	0.01%	85
2016 Q1	$56K	Hold	15,935	–	–	0.01%	91
2015 Q4	$56K	Hold	15,935	–	–	0.01%	90
2015 Q3	$80K	Hold	15,935	–	–	0.01%	88
2015 Q2	$102K	Hold	15,935	–	–	0.02%	95
2015 Q1	$112K	Buy	+15,935	New	+$115K	0.02%	92

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Nottingham Advisors's PDLI Position: Q4 2017 in Review

Nottingham Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2017, closing a stake of 15,935 shares — an estimated $54K sold.

Nottingham Advisors first reported a position in PDLI in Q1 2015 and held it in 11 quarters. The position peaked at $112K in Q1 2015. 187 funds tracked by Wall St. Rank hold PDLI as of Q4 2017.

Nottingham Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2017 after selling out during the quarter.
Nottingham Advisors sold 15,935 PDL BioPharma, Inc. shares in Q4 2017, an estimated $54K.
Nottingham Advisors first reported a position in PDL BioPharma, Inc. in Q1 2015 and held it in 11 quarters.
Nottingham Advisors's PDL BioPharma, Inc. position peaked at $112K in Q1 2015.
187 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2017.

Based on Nottingham Advisors's 13F filing for Q4 2017, filed 29 Jan 2018.